Welcome to our dedicated page for Natera news (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.
Natera, Inc. develops and commercializes cell-free DNA and genetic testing for oncology, women’s health and organ health. Company updates commonly cover financial results, revenue trends, laboratory operations and publications supporting tests such as Signatera, Prospera, Panorama and Horizon.
Recurring news also includes oncology molecular residual disease applications, clinical evidence presented at medical meetings, transplant rejection surveillance data, collaborations using Natera assays in drug trials, and patent or litigation developments tied to its MRD technology. The company reports through CLIA-certified and CAP-accredited laboratory operations and through Foresight Diagnostics, its subsidiary.
Natera (NASDAQ: NTRA) will present new data on its Prospera donor-derived cell-free DNA (dd-cfDNA) test at the American Transplant Congress (ATC) 2024 from June 1–5. The company will showcase 18 abstracts, including results from the ProActive study, the largest prospective dd-cfDNA study in kidney transplant recipients. Key findings highlight the Prospera Kidney test's efficacy in predicting organ rejection, with results demonstrating a high predictive value (AUC range: 92-96%). Additional data show significant variation in dd-cfDNA levels, suggesting its utility in ongoing surveillance and risk stratification for adverse outcomes.
Natera, a global leader in cell-free DNA and genetic testing, will present at the 2024 Leerink Partners Healthcare Crossroads Conference. The presentation is scheduled for Thursday, May 30, 2024, at 8:40 a.m. PT (11:40 a.m. ET). The event will be live-streamed on the investor relations section of Natera's website, with a replay available shortly after.
Natera (NASDAQ: NTRA) will present new data at the 2024 ASCO Annual Meeting, May 31 – June 4, 2024. The data spans multiple cancer types, including breast, colorectal (CRC), lung, melanoma, esophageal, and urothelial cancers. Natera's Signatera™ and Empower™ tests will be highlighted in one oral and 13 poster presentations. Key studies include the CIRCULATE-Japan GALAXY study, showcasing the prognostic and predictive utility of Signatera for CRC. Natera expects topline results from the ALTAIR phase III trial by August 2024. Presentations will demonstrate ctDNA's role in detecting minimal residual disease and monitoring treatment responses in various cancers.
Natera, Inc. (NASDAQ: NTRA) reported positive first quarter financial results for 2024, with $367.7 million in total revenues, a 52.1% increase from the previous year. The company achieved a gross margin of 56.7%, processed 735,800 tests, and had a net loss of $67.6 million. Natera expects total revenue of $1.42 billion to $1.45 billion for 2024.
Natera, Inc. announced a new publication in JCO Precision Oncology showcasing the effectiveness of its Signatera test in detecting breast cancer recurrence early. The study involved 156 early-stage breast cancer patients followed for up to 12 years post-surgery. Signatera detected relapse 38 months earlier than imaging, with an 88.2% sensitivity rate. Patients testing positive for ctDNA had worse survival outcomes. The study emphasizes the importance of early recurrence detection and long-term monitoring in breast cancer patients.
Natera, Inc. (NASDAQ: NTRA) will report its first quarter 2024 results on May 9. The company is a global leader in cell-free DNA and genetic testing. The earnings conference call will take place at 1:30 p.m. PT (4:30 p.m. ET) on the same day.
Natera, Inc. (NASDAQ: NTRA) has launched a new cfDNA-based fetal RhD test to support Ob/Gyn physicians and patients during a nationwide shortage of RhIg therapy. The test offers 100% sensitivity and >99% specificity, and can be conducted as early as nine weeks gestation. This initiative is important to prevent complications from alloimmunization in pregnancies where the maternal blood type is RhD-negative and the fetal blood type is RhD-positive. The product launch was supported by a large clinical validation study with over 650 patients, demonstrating Natera's commitment to accurate and reliable diagnostics in women's health.
Summary not available.
Summary not available.
Summary not available.